C. Schiffer

C. Schiffer, P. Chandrasekar, P. Chandrasekar, 2013, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

SOME ASPECTS OF RECENT ADVANCES IN THE USE OF BLOOD CELL COMPONENTS

C. Schiffer, 1978, British journal of haematology.

Incidence of thrombocytopenia and serious hemorrhage among patients with solid tumors

J. Dutcher, C. Schiffer, J. Aisner, 1984, Cancer.

Prophylactic platelet transfusion

C. Schiffer, 1992, Transfusion.

The relationship between the duration of platelet storage and the development of transfusion reactions

C. Schiffer, E. Lee, R. Sridhara, 1998, Transfusion.

Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients.

Edward J. Lee, C. Schiffer, H. Braine, 2005, Blood.

"Acute myelogenous leukemia like" translocations in CML blast crisis: two new cases of inv(16)/t(16;16) and a review of the literature.

C. Schiffer, A. Mohamed, B. Patel, 2006, Leukemia research.

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study.

T. Brümmendorf, H. Kantarjian, J. Cortes, 2014, Blood.

An evaluation of ponatinib as a therapy in adult patients with resistant/intolerant chronic-phase chronic myeloid leukemia

C. Schiffer, Malini Surapaneni, Jay Yang, 2022, Expert review of hematology.

Ponatinib Dose-Ranging Study in Chronic-Phase Chronic Myeloid Leukemia: A Randomized, Open-Label Phase 2 Clinical Trial.

G. Rosti, J. Cortes, M. Deininger, 2021, Blood.

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity

S. Mustjoki, J. Cortes, K. Porkka, 2016, Cancer.

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia

C. Schiffer, R. Ramchandren, 2009, Biologics : targets & therapy.

Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and leukemia group B study 8583

C. Bloomfield, J. Testa, S. George, 1993 .

First-line treatment for patients with CML in chronic phase: why imatinib is an appropriate choice.

C. Schiffer, 2013, Oncology.

Which TKI should be recommended as initial treatment for CML in chronic phase?

C. Schiffer, 2012, Oncology.

Myelodysplastic syndromes standardized response criteria: further definition.

B. Cheson, P. Greenberg, H. Kantarjian, 2001, Blood.

Transplantation for Myeloma - Now or Later?

J. Zonder, C. Schiffer, 2017, The New England journal of medicine.

Molecular Monitoring of BCR-ABL Transcripts in Patients With Chronic Myelogenous Leukemia: Is High Sensitivity of Clinical Value?

M. Norkin, C. Schiffer, 2010, Current hematologic malignancy reports.

Frozen autologous platelet transfusion for patients with leukemia.

C. Schiffer, J. Aisner, P. Wiernik, 1978, The New England journal of medicine.

Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study.

C. Bloomfield, K. Mrózek, R. Mayer, 1997, Blood.

Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.

Edward J. Lee, C. Bloomfield, G. Petroni, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Deficiency of neutrophilic granule membrane glycoproteins in the myelodysplastic syndromes: a common deficiency in 216 patients studied by the Cancer and Leukemia Group B.

C. Bloomfield, B. Peterson, F. Davey, 1997, Leukemia research.

Opportunities for the use of thrombopoietic growth factors

C. Schiffer, 1998, Stem cells.

Potential Clinical Applications of Thrombopoietic Growth Factors

C. Schiffer, 1997 .

Chronic lymphocytic leukemia: recommendations.

M. Grever, B. Cheson, M. Oken, 1989, Annals of internal medicine.

Commentary on: ‘Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia’

C. Schiffer, 2016, Leukemia.

Myelodysplasia: the good, the fair and the ugly.

C. Schiffer, 2007, Best practice & research. Clinical haematology.

Marrow failure.

J. Lipton, E. Sloand, C. Schiffer, 2004, Hematology. American Society of Hematology. Education Program.

Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival.

J. Dutcher, C. Schiffer, P. Wiernik, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Perspective on the Treatment of Acute Lymphoblastic Leukemia in Adults

C. Schiffer, 2011 .

the use and interpretation of monitoring methods modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on Monitoring the response and course of chronic myeloid leukemia in the

H. Kantarjian, C. Schiffer, Dan Jones, 2013 .

Hematopoietic Growth Factors in Patients with Acute Leukemia

C. Schiffer, 2003 .

Low dose 5-azacytidine is ineffective for remission induction in patients with acute myeloid leukemia.

C. Schiffer, E. Lee, D. Hogge, 1990, Leukemia.

Treatment of the blast crisis of chronic myelogenous leukemia with 5-azacitidine and VP-16-213.

C. Schiffer, P. Wiernik, R. DeBellis, 1982, Cancer treatment reports.

Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis.

S. Phuphanich, T. Batchelor, M. Chamberlain, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Infectious Complications of Tyrosine Kinase Inhibitors in Hematological Malignancies.

C. Schiffer, A. Kin, 2020, Infectious disease clinics of North America.

Discontinuation of tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia – You can do this at home if you read the instructions

C. Schiffer, 2019, Haematologica.

Five Year Follow-Up Results of a Phase II Trial in Patients with Late Chronic Phase (L-CP) Chronic Myeloid Leukemia (CML) Treated with Imatinib Who Are Refractory/Intolerant of Interferon-α.

C. Sawyers, H. Kantarjian, B. Druker, 2005 .

Four Years of Follow-Up of 1027 Patients with Late Chronic Phase (L-CP), Accelerated Phase (AP), or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Treated with Imatinib in Three Large Phase II Trials.

C. Sawyers, H. Kantarjian, B. Druker, 2004 .

The evolution of dasatinib dosage over the years and its relevance to other anticancer medications

C. Schiffer, 2018, Cancer.

Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.

K. Flynn, C. Schiffer, A. D’Souza, 2019, The oncologist.

What if conventional-dose imatinib fails?

C. Schiffer, 2007 .

Comment on Kantarjian et al , page 5143 What if conventional-dose imatinib fails ?

C. Schiffer, 2007 .

A prospective ophthalmic evaluation of patients with acute myeloid leukemia: correlation of ocular and hematologic findings.

C. Schiffer, E. Lee, S. Kelman, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome.

F. Appelbaum, R. Larson, M. Tallman, 2000, Blood.

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?

C. Schiffer, E. Atallah, 2020, Haematologica.

Promyelocytic blast crisis in chronic granulocytic leukemia with 15;17 translocation.

J. Testa, S. Misawa, C. Schiffer, 1984, Leukemia research.

Presenting Signs and Symptoms

R. Stone, C. Schiffer, 2003 .

Platelet Transfusion Therapy for Patients with Cancer

C. Schiffer, 1983 .

Effect of histocompatibility factors on pulmonary retention of indium‐111‐labeled granulocytes

G. Johnston, J. Dutcher, C. Schiffer, 1990, American journal of hematology.

Granulocyte transfusion therapy and amphotericin B: Adverse reactions?

J. Dutcher, C. Schiffer, J. Aisner, 1989, American journal of hematology.

Intravenous immune globulin for patients alloimmunized to random donor platelet transfusion

Edward J. Lee, C. Schiffer, C. Schiffer, 1987, Transfusion.

Platelets for transfusion: collection, storage and clinical efficacy

C. Schiffer, D. Hogge, 1985 .

Alloimmunization following platelet transfusion: the absence of a dose-response relationship.

J. Dutcher, C. Schiffer, J. Aisner, 1981, Blood.

Platelet transfusion therapy. One-hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations.

C. Schiffer, J. Aisner, P. Wiernik, 1980, JAMA.

A study of HLA antigens and haplotypes in a population of Caucasians with acute non-lymphocytic leukemia.

R. Simon, P. Terasaki, C. Schiffer, 1979, Leukemia research.

Granulocyte Transfusions: Evaluation of Factors Influencing Results and a Comparison of Filtration and Intermittent Centrifugation Leukapheresis

C. Schiffer, J. Aisner, P. Wiernik, 1978, British journal of haematology.

Antibody response in patients with acute nonlymphocytic leukemia

M. Mardiney, C. Schiffer, P. Wiernik, 1976, Cancer.

Clinical experience with transfusion of granulocytes obtained by continuous flow filtration leukopheresis.

C. Schiffer, J. Aisner, P. Wiernik, 1975, The American journal of medicine.

Granulocyte transfusions in haematopoietic cell transplants and leukaemia: the phoenix or beating a dead horse?

R. Gale, H. Lazarus, C. Schiffer, 2021, Bone Marrow Transplantation.

Should all adults with acute lymphocytic leukemia receive allogeneic stem cell transplantation in first remission

C. Schiffer, K. Carlson, E. Atallah, 2014 .

Transient neutropenia induced by transfusion of blood exposed to nylon fiber filters.

C. Schiffer, J. Aisner, P. Wiernik, 1975, Blood.

antibodies Adult acute lymphoblastic leukemia phenotypes defined by monoclonal

C. Bloomfield, T. Lebien, J. Minowada, 2011 .

Interim analysis of a phase II study of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg (R)) given in combination with cytarabine and daunorubicin to patients < 60 years old with untreated acute myeloid leukemia.

M. Berger, G. Juliusson, M. Tallman, 2002 .

Zinc toxicity from massive and prolonged coin ingestion in an adult.

C. Schiffer, M. Ehrinpreis, F. Siddiqui, 2008, The American journal of the medical sciences.

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Thomas J. Smith, Gary H Lyman, Thomas J Smith, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytogenetic Subtype Cytarabine Intensification in Acute Myeloid Leukemia Varies by Frequency of Prolonged Remission Duration after High-Dose Updated

C. Bloomfield, J. Byrd, S. Patil, 2006 .

Unusual karyotypic changes and B cell involvement in a case of lymph node blast crisis of chronic myelogenous leukemia.

J. Testa, S. Misawa, C. Schiffer, 1984, Blood.

Use of myeloid growth factors for patients with febrile neutropenia: Plus Ça Change, Plus C'est La Même Chose

C. Schiffer, 2005, Pediatric blood & cancer.

Acute eosinophilic leukemia with a (10;11) chromosomal translocation.

J. Testa, C. Schiffer, S. Fischkoff, 1988, Leukemia.

Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients.

L. Doyle, D. Ross, Weidong Yang, 1996, Leukemia.

How to Effectively Decrease Patient Co-Payments of High-Cost Drugs Through Innovation: Lessons From the Karmanos Specialty Pharmacy

C. Schiffer, Erlene K Seymour, Lucius Daniel, 2021, JCO oncology practice.

CML: how low can you go?

C. Schiffer, 2010, Blood.

Intensive postremission therapy in adults with acute nonlymphocytic leukemia using various dose schedules of ara-C: a progress report from the CALGB. Cancer and Leukemia Group B.

K. Rai, R. Mayer, R. Silver, 1987, Seminars in oncology.

Cancer and Leukemia Group B (CALGB) Studies with Hematopoietic Growth Factors in Patients with Acute Myeloid Leukemia

R. Stone, B. Peterson, C. Schiffer, 1994 .

Long‐term follow‐up of cancer and leukemia group B studies in acute myeloid leukemia

R. Larson, R. Dodge, C. Schiffer, 1997, Cancer.

Metabolism of ara-C by blast cells from patients with ANLL.

S. Akman, D. Ross, C. Schiffer, 1986, Blood.

Use of ‘Split’ Plateletpheresis Products for Alloimmunized Patients

Edward J. Lee, C. Schiffer, D. Norris, 1994, Vox sanguinis.

International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data.

M. Loh, E. Estey, M. Cazzola, 2022, Blood.

BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.

C. Schiffer, Charles A Schiffer, 2007, The New England journal of medicine.

Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583.

C. Bloomfield, J. Testa, S. George, 1993, Blood.

Racial disparities in time to hematopoietic cell transplant among patients with hematologic malignancies at a large urban academic center

C. Schiffer, Seongho Kim, M. Fiala, 2022, Bone Marrow Transplantation.

Acute promyelocytic leukemia—clinical management of 15 patients

C. Schiffer, P. Wiernik, P. Daly, 1980, American journal of hematology.

Double Esterase Staining andOther Neutrophilic Granule Abnormalities in 237 Patients with the Myelodysplastic Syndrome Studied by the Cancer and Leukemia Group B

C. Bloomfield, B. Peterson, F. Davey, 1998, Acta Haematologica.

All-Trans-Retinoic Acid Maintenance for Acute Promyelocytic Leukemia

C. Bloomfield, F. Appelbaum, C. Willman, 2001 .

Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.

Z. Cabantchik, P. Greenberg, G. Warsi, 2010, Leukemia research.

The significance of CD34 and TdT determinations in patients with untreated de novo acute myeloid leukemia.

J. Testa, J. Yang, C. Schiffer, 1992, Leukemia.

Trisomy 21 as the sole acquired chromosomal abnormality in children with acute lymphoblastic leukemia.

C. Bloomfield, R. Larson, C. Schiffer, 1992 .

Acute Lymphoblastic Leukemia in Adults

C. Schiffer, 2002 .

Cancer and Leukemia Group B (CALGB) studies in adult acute lymhocytic leukemia.

C. Bloomfield, R. Larson, C. Schiffer, 1992, Leukemia.

Acute myeloid leukemia in adults: where do we go from here?

C. Schiffer, 2001, Cancer Chemotherapy and Pharmacology.

Randomized clinical comparison of daunorubicin (NSC-82151) alone with a combination of daunorubicin, cytosine arabinoside (NSC-63878), 6-thioguanine (NSC-752), and pyrimethamine (NSC-3061) for the treatment of acute nonlymphocytic leukemia.

M. O’connell, C. Schiffer, J. Aisner, 1976, Cancer treatment reports.

Granulocyte transfusion therapy 2006: The comeback kid?

C. Schiffer, 2006, Medical mycology.

Divide and conquer: stomping leukemia cells by stimulating them to grow

C. Schiffer, 2005 .

Storage and transfusion of platelets collected by an automated two‐ stage apheresis procedure

T. Simon, C. Schiffer, D. Huestis, 1992, Transfusion.

Platelet storage for 7 days in second‐generation blood bags

C. Schiffer, D. Hogge, B. W. Thompson, 1986, Transfusion.

Platelet Transfusion: Quality Control

C. Schiffer, 1984 .

Which are the Parameters to be Controlled in Platelet Concentrates in Order that They May be Offered to the Medical Profession as a Standardized Product with Specific Properties?

R. Kahn, R. Aster, C. Schiffer, 1981, Vox sanguinis.

Cryopreservation of platelet concentrates using glycerol‐glucose

C. Schiffer, B. Kotelba-Witkowska, 1982, Transfusion.

Successful transfusion of platelets cryopreserved for more than 3 years.

C. Schiffer, J. Aisner, P. Wiernik, 1979, Blood.

Clinical Experience with Transfusion of Cryopreserved Platelets

C. Schiffer, J. Aisner, P. Wiernik, 1976, British journal of haematology.

Management of Alloimmunized, Refractory Patients in Need of Platelet Transfusions

C. Schiffer, 1997 .

PLATELET CRYOPRESERVATION USING DIMETHYL SULFOXIDE

J. Dutcher, C. Schiffer, J. Aisner, 1983, Annals of the New York Academy of Sciences.

The value of 10‐minute posttransfusion platelet counts

Edward J. Lee, C. Schiffer, C. Schiffer, 1988, Transfusion.

Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology.

J M Rainey, K. C. Anderson, P. Rebulla, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Effect of Hydroxyethyl Starch on In Vitro Platelet and Granulocyte Function

C. Schiffer, J. Aisner, J. Wolff, 2003, Transfusion.

Acute myeloblastic leukemia with extensive erythrophagocytosis mimicking malignant histiocytosis.

C. Schiffer, S. Hassinger, C. Sun, 1989, American journal of clinical pathology.

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Francisco Cervantes, Simona Soverini, Giovanni Martinelli, 2013, Blood.

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.

R. Mayer, C. Schiffer, J. Moore, 1994, The New England journal of medicine.

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.

C. Bloomfield, M. Grever, B. Cheson, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.

C. Bloomfield, R. Larson, S. George, 2005, Blood.

Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered.

C. Bloomfield, J. Byrd, M. Qumsiyeh, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

C. Bloomfield, J. Byrd, S. Patil, 1998, Cancer research.

Seminars in oncology

C. Schiffer, 2001 .

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.

J. Armitage, James R. Anderson, M. Somerfield, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Methicillin-Associated Thrombocytopenia

H. Weinstein, C. Schiffer, P. Wiernik, 1976 .

Improved prognosis for granulocytopenic patients with gram-negative bacteremia.

C. Schiffer, P. Wiernik, S. Schimpff, 1980, The American journal of medicine.

Granulocyte transfusion therapy.

R. Strauss, H. Klein, C. Schiffer, 1996, Seminars in hematology.

Sustained post‐transfusion granulocyte count increments following transfusion of leukocytes obtained from donors with chronic myelogenous leukemia

J. Dutcher, C. Schiffer, J. Aisner, 1983, American journal of hematology.

Principles of granulocyte transfusion therapy.

C. Schiffer, 1977, The Medical clinics of North America.

Rational Approach to Granulocyte Transfusion Therapy

C. Schiffer, J. Aisner, 1980 .

Alloimmunization following prophylactic granulocyte transfusion.

C. Schiffer, J. Aisner, P. Wiernik, 1979, Blood.

Gravity leukapheresis--a simple method of leukocyte collection for transfusion or in vitro study.

C. Schiffer, J. Aisner, P. Wiernik, 1979, Leukemia research.

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

C. Bloomfield, E. Estey, W. Hiddemann, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acute myeloid leukaemia in adults

F. Ferrara, C. Schiffer, 2013, The Lancet.

Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002

F. E. Bertrand, G. Daley, C. Pui, 2003, Leukemia.

The effect of lymphocytotoxic antibody reactivity on the results of single antigen mismatched platelet transfusions to alloimmunized patients.

C. Schiffer, R. Fletcher, E. Lee, 1996, Blood.

Platelet transfusion therapy for alloimmunized patients: selective mismatching for HLA B12, an antigen with variable expression on platelets.

C. Schiffer, E. Lee, E. Lee, 1989, Blood.

The ineffectiveness of random donor platelet transfusion in splenectomized, alloimmunized recipients.

J. Dutcher, C. Schiffer, J. Aisner, 1984, Blood.

Long-term follow-up patients with leukemia receiving platelet transfusions: identification of a large group of patients who do not become alloimmunized.

J. Dutcher, C. Schiffer, J. Aisner, 1981, Blood.

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol

C. Bloomfield, W. Woods, F. Appelbaum, 2022 .

Acute Myeloid Leukemia in Adults

R. Stone, C. Schiffer, 2003 .

A phase II trial of didemnin B in myeloma

B. Peterson, R. Weiss, C. Schiffer, 1994, Investigational New Drugs.

Induction of premalignant and malignant changes in normal human prostate by N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) in organ culture

F. Mostofi, B. Trump, C. Schiffer, 1978 .

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).

C. Bloomfield, J. Byrd, R. Larson, 2002, Blood.

Increased leukocyte alkaline phosphatase activity following transfusion of leukocytes from a patient with chronic myelogenous leukemia.

C. Schiffer, J. Aisner, P. Wiernik, 1979, The American journal of medicine.

Application of FISH to complex chromosomal rearrangements associated with chronic myelogenous leukemia.

S. Schwartz, B. Sullivan, C. Schiffer, 1995, Cancer genetics and cytogenetics.

Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.

M. Caligiuri, C. Bloomfield, R. Larson, 2002, Blood.

Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine.

Edward J. Lee, C. Bloomfield, S. George, 2001, Blood.

Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia

Stephen L. George, Edward J. Lee, S. George, 1995 .

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.

B. Cheson, R. Larson, F. Appelbaum, 2000, The New England journal of medicine.

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

J. Holland, R. Larson, R. Stone, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Report of an international working group to standardize response criteria for myelodysplastic syndromes.

B. Cheson, P. Greenberg, H. Kantarjian, 2000, Blood.

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

J. Reeves, H. Deeg, P. Greenberg, 2008, Blood.

Retinoid induced apoptosis in leukemia cells through a retinoic acid nuclear receptor-independent pathway.

A. Rishi, M. Dawson, B. Shroot, 1997, Blood.

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

B. Cheson, P. Greenberg, H. Kantarjian, 2006, Blood.

All-trans-retinoic acid in acute promyelocytic leukemia.

C. Bloomfield, F. Appelbaum, C. Willman, 1997, The New England journal of medicine.

Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a Cancer and Leukemia Group B study

C. Bloomfield, G. Rosner, R. Schilsky, 1995, Cancer Chemotherapy and Pharmacology.

Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.

Edward J. Lee, M. Caligiuri, C. Bloomfield, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.

K. Weinfurt, J. Radich, R. Larson, 2020, JAMA oncology.

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

J. Byrd, R. Larson, F. Appelbaum, 2005, Blood.

Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study.

C. Bloomfield, K. Mrózek, S. Bigner, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Storage of platelet concentrates using ion exchange resin charged with dibasic phosphate.

C. Schiffer, D. Harmening-Pittiglio, B. Kotelba-Witkowska, 1981 .

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.

Sante Tura, Thomas Fischer, Alois Gratwohl, 2002, Blood.

Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia.

Edward J. Lee, J. Testa, C. Schiffer, 1989, Blood.

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

M. Baccarani, C. Sawyers, H. Kantarjian, 2002, Blood.

Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti‐B4‐blocked ricin or high‐dose cytarabine

C. Bloomfield, C. Reynolds, J. Sklar, 2003, Cancer.

Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study.

C. Bloomfield, F. Appelbaum, C. Willman, 1997, Blood.

Very late recurrences of leukemia: why does leukemia awake after many years of dormancy?

M. Norkin, C. Schiffer, J. Uberti, 2011, Leukemia research.

Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.

C. Bloomfield, R. Larson, K. Mrózek, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience.

C. Bloomfield, R. Larson, M. L. Le Beau, 1999, Blood.

Reversal of granulocyte adherence to nylon fibers using local anesthetic agents: possible application to filtration leukapheresis.

C. Schiffer, J. Aisner, F. Sanel, 1977, Blood.

Commentary on the prescient observations made by Emil J Freireich in Effectiveness of platelet transfusion in leukemia and aplastic anemia (Transfusion 1966; 6: 50–54)

C. Schiffer, 2022, Transfusion.

The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B.

C. Schiffer, E. Henderson, R. Silver, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Differentiation of leukemia cells to polymorphonuclear leukocytes in patients with acute nonlymphocytic leukemia.

B. Vogelstein, E. Fearon, B. Zehnbauer, 1986, The New England journal of medicine.

Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL1

R. Larson, R. Hehlmann, C. Schiffer, 2003, Leukemia.

If at first you don't succeed: stem-cell transplantation for acute myeloid leukemia after first relapse.

C. Schiffer, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111.

Edward J. Lee, C. Bloomfield, R. Larson, 1998, Blood.

Adult acute lymphoblastic leukemia phenotypes defined by monoclonal antibodies.

C. Bloomfield, T. Lebien, J. Minowada, 1985, Blood.

A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy.

C. Schiffer, R. Sims-McCallum, Chin Y Liu, 2005, Leukemia research.

Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma

Edward J. Lee, C. Bloomfield, R. Larson, 2004, Cancer.

Evaluation of levamisole as an adjuvant to chemotherapy for treatment of ANLL

C. Schiffer, P. Wiernik, S. Schimpff, 1983, Cancer.

Current status of granulocyte transfusion therapy.

C. Schiffer, J. Aisner, P. Wiernik, 1977, Progress in clinical and biological research.

Granulocyte Harvest for Transfusion: Donor Response to Repeated Leukapheresis

C. Schiffer, P. Wiernik, J. A. Reilly, 2003, Transfusion.

Evidence for rapid rapid mobilization of platelets from the spleen during intensive plateletpheresis

Edward J. Lee, C. Schiffer, 1985, American journal of hematology.

Collection of platelets depleted of red and white cells with the “surge pump” adaptation of a blood cell separator

C. Schiffer, D. Hogge, 1983, Transfusion.

Panel VIII: Platelet concentrates: Functional considerations, storage, and quality control

C. Schiffer, S. Murphy, A. Katz, 1983 .

Platelet transfusions from single donors

C. Schiffer, S. Slichter, 1982 .

Intensive Multiunit Plateletpheresis of Normal Donors

C. Schiffer, P. Wiernik, D. Buchholz, 1974, Transfusion.

Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22).

C. Bloomfield, J. Byrd, D. Arthur, 1997, Blood.

Failure of high‐dose I.V. Gammaglobulin in the treatment of spontaneously acquired factor VIII inhibitors

C. Schiffer, M. Heyman, S. Needleman, 1988, American journal of hematology.

Trisomy 13: A New Recurring Chromosome Abnormality in Acute Leukemia

C. Bloomfield, H. Döhner, J. Testa, 1990 .

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

J. Byrd, R. Larson, K. Rai, 2003, Blood.

Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline.

M. Gorman, D. Cope, J. Ligibel, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Supportive care: issues in the use of blood products and treatment of infection.

C. Schiffer, J. Wade, 1987, Seminars in oncology.

adult acute nonlymphocytic leukemia Diaziquone given as a continuous infusion is an active agent for relapsed

M. Egorin, Ej Lee, C. Schiffer, 2011 .

ABO compatibility can influence the results of platelet transfusion

C. Schiffer, E. Lee, E. Lee, 1989, Transfusion.

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Francisco Cervantes, Ryuzo Ohno, Richard E. Clark, 2013, Blood.

Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporin A and cremophor EL.

D. Ross, C. Schiffer, E. Lee, 1994, Blood.

Effects of verapamil on in vitro intracellular accumulation and retention of daunorubicin in blast cells from patients with acute nonlymphocytic leukemia.

D. Ross, C. Schiffer, C. Joneckis, 1986, Blood.

Genetic biomarkers in acute myeloid leukemia: will the promise of improving treatment outcomes be realized?

C. Schiffer, Jay Yang, 2012, Expert review of hematology.

Pattern of Duplicate Presentations at National Hematology-Oncology Meetings: Influence of the Pharmaceutical Industry.

C. Schiffer, R. Ramchandren, 2016, Journal of oncology practice.

Phase IB Study of PKC412, an Oral FLT3 Kinase Inhibitor, in Sequential and Simultaneous Combinations with Daunorubicin and Cytarabine (DA) Induction and High-Dose Cytarabine Consolidation in Newly Diagnosed Patients with AML.

H. Kantarjian, J. Cortes, R. Stone, 2004 .

Lymphoblastic Leukemia: Cancer and Leukemia Group B Study 8364 Value of Immunophenotype in Intensively Treated Adult Acute

C. Bloomfield, M. Czuczman, R. Larson, 2011 .

Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022.

Edward J. Lee, R. Dodge, J. Kolitz, 1997, Blood.

Fifty Years of Clinical Research by the Leukemia Committee of the Cancer and Leukemia Group B

R. Larson, R. Mayer, R. Stone, 2006, Clinical Cancer Research.

Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

P. Rebulla, M. Troner, C. Schiffer, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib.

C. Schiffer, J. Valent, 2011, Leukemia research.

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

C. Schiffer, H. Kantarjian, J. Cortes, 2012, Leukemia.

Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute‐sponsored working group

M. Grever, B. Cheson, M. Oken, 1988, American journal of hematology.

Intravenous Gammaglobulin in Alloimmunized Platelet Transfusion Recipients

J. Dutcher, C. Schiffer, J. Aisner, 2017 .

They took a mulligan and mostly got it right … the issue of prophylactic platelet transfusion for patients receiving autologous stem cell transplantation

C. Schiffer, 2014, Transfusion.

Haematological cancer: Prophylactic platelet transfusion is frequently not necessary

C. Schiffer, 2013, Nature Reviews Clinical Oncology.

Differentiation of blast cells in acute nonlymphocytic leukemia.

B. Vogelstein, E. Fearon, B. Zehnbauer, 1986, The New England journal of medicine.

Management of patients refractory to platelet transfusion.

L. Sherman, A. Bracey, C. Schiffer, 2007, Archives of pathology & laboratory medicine.

Platelet transfusions administered to patients with splenomegaly

C. Schiffer, M. A. Hussein, E.J. Lee, 1990, Transfusion.

Selection of histocompatible apheresis platelet donors by cross-matching random donor platelet concentrates.

C. Schiffer, E. Lee, E. Lee, 1992, Blood.

High-dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients.

J. Dutcher, C. Schiffer, J. Aisner, 1984, Blood.

Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute myelogenous leukemia in 1st remission.

M. Horowitz, K. Rai, R. Gale, 1999, Leukemia research.

Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics.

M. Caligiuri, C. Bloomfield, A. de la Chapelle, 1998, Cancer research.

Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study

R. Larson, H. Hurwitz, K. Rai, 2002, Cancer Chemotherapy and Pharmacology.

White cell reduction in platelet concentrates and packed red cells by filtration: a multicenter clinical trial. The Trap Study Group

Edward J. Lee, M. J. Gillespie, C. Schiffer, 1995, Transfusion.

Randomized Control led Tria l o f Azac i t id ine in Pat ients With the Myelodysplas t ic Syndrome : A Study of the Cancer and Leukemia Group B

J. Holland, R. Larson, R. Stone, 2017 .

Mitoxantrone and Constant Infusion Etoposide for Relapsed and Refractory Acute Myelocytic Leukemia

C. Schiffer, J. Holland, R. Davis, 1990, American journal of clinical oncology.

Lois Shepherd, John D Hines, R. Larson, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia.

Edward J. Lee, C. Bloomfield, R. Larson, 2004, Blood.

Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia

E. Estey, F. Appelbaum, R. Walter, 2012, Haematologica.

Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011.

R. Larson, F. Appelbaum, K. Rai, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular characterization of AML: a significant advance or just another prognostic factor?

C. Schiffer, 2008, Best practice & research. Clinical haematology.

A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia.

R M Stone, R. Larson, R. Stone, 2000, Blood.

Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.

S. George, R. Dodge, R. Stone, 1995, The New England journal of medicine.

Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group.

C. Bloomfield, R. Larson, E. Vellenga, 2010, Blood.

Patients with isolated trisomy 8 in acute myeloid leukemia are not cured with cytarabine-based chemotherapy: results from Cancer and Leukemia Group B 8461.

C. Bloomfield, J. Byrd, M. Qumsiyeh, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.

J. Holland, R. Larson, C. Decastro, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapy for chronic myelogenous leukemia in blast crisis with etoposide and 5-azacitidine administered by continuous infusion: a Cancer and Leukemia group B Study.

C. Schiffer, J. Cuttner, M. Coleman, 1985, Cancer treatment reports.

Phase 2 Study of Ibrutinib in Classic and Variant Hairy Cell Leukemia.

Jeffrey A Jones, M. Grever, G. Lozanski, 2021, Blood.

Challenges in the Clinical Application of the American Society of Clinical Oncology Value Framework: A Medicare Cost-Benefit Analysis in Chronic Lymphocytic Leukemia

J. D. de Souza, C. Schiffer, Erlene K Seymour, 2017, Journal of oncology practice.

Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.

C. Bloomfield, R. Larson, K. Mrózek, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical characteristics of patients with de novo acute myeloid leukaemia and isolated trisomy 11: a Cancer and Leukemia Group B study

C. Bloomfield, M. Qumsiyeh, K. Mrózek, 1998, British journal of haematology.

Working Group (IWG) response criteria in myelodysplasia Clinical application and proposal for modification of the International

P. Greenberg, H. Kantarjian, J. Bennett, 2009 .

Treatment of the 5 q – Syndrome Pierre Fenaux and Charikleia Kelaidi Myelodysplastic Syndromes

P. Fenaux, S. Nimer, J. Vardiman, 2006 .

Intensive maintenance therapy improves survival in adult acute nonlymphocytic leukemia: an eight-year follow-up.

J. Dutcher, C. Schiffer, P. Wiernik, 1988, Leukemia.

Minimally differentiated acute nonlymphocytic leukemia: a distinct entity.

J. Testa, C. Schiffer, E. Lee, 1987, Blood.

Quality of life for adult leukemia survivors treated on clinical trials of cancer and leukemia group B during the period 1971‐1988

J. Holland, R. Mayer, R. Weiss, 1997, Cancer.

A clinical program of platelet cryopreservation.

J. Dutcher, C. Schiffer, J. Aisner, 1982, Progress in clinical and biological research.

Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study.

C. Bloomfield, K. Mrózek, R. Mayer, 1997, Blood.

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study.

M. Liedtke, H. Kantarjian, W. Stock, 2017, Blood advances.

Improvement of pulmonary function with imatinib mesylate in bronchiolitis obliterans following allogeneic hematopoietic cell transplantation.

D. Weisdorf, C. Schiffer, N. Majhail, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

H. Kantarjian, J. Cortes, R. Stone, 2006 .

Interferon studies in the treatment of patients with leukemia.

C. Schiffer, 1991, Seminars in oncology.

Morphologic characteristics of erythroleukemia (Acute Myeloid Leukemia; FAB‐M6): A CALGB study

C. Bloomfield, J. Griffin, R. Mayer, 1995, American journal of hematology.

Defect in Acute Myeloid Leukemia with Trisomy 11 as a Recurrent Molecular ALL 1 Partial Tandem Duplication of Updated

M. Caligiuri, C. Bloomfield, C. Croce, 2006 .

Platelet Aggregation during and after General Anesthesia and Surgery

C. Schiffer, K. Lichtenfeld, Martin Helrich, 1979, Anesthesia and analgesia.

Association of the translocation (15;17) with malignant proliferation of promyelocytes in acute leukemia and chronic myelogenous leukemia at blastic crisis.

J. Testa, S. Misawa, C. Schiffer, 1986, Blood.

A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study.

C. Schiffer, K. Dear, C. Schiffer, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chronic lymphocytic leukemia presenting in association with aplastic anemia

M. Keating, J. Zonder, C. Schiffer, 2002, American journal of hematology.

A phase I trial of carboplatin and etoposide given as continuous infusions to adults with leukemia.

C. Schiffer, C. Carter, E. Lee, 1993, Leukemia.

Functional and morphologic characteristics of the leukemic cells of a patient with acute monocytic leukemia: correlation with clinical features

C. Schiffer, P. Wiernik, F. Sanel, 1975 .

The artful management of older patients with acute myeloid leukemia

C. Schiffer, Jay Yang, 2016, Expert review of hematology.

Dasatinib in imatinib‐resistant or ‐intolerant chronic‐phase, chronic myeloid leukemia patients: 7‐year follow‐up of study CA180‐034

H. Kantarjian, J. Cortes, G. Saglio, 2016, American journal of hematology.

Studies of ara-C metabolism in acute leukemia.

S. Akman, D. Ross, C. Schiffer, 1987, Seminars in oncology.

Phase I and pharmacokinetic trial of carboplatin in refractory adult leukemia.

M. Egorin, C. Schiffer, D. V. Van Echo, 1988, Journal of the National Cancer Institute.

Should All Platelet Concentrates Issued Be Leukocyte‐Poor?

C. Schiffer, H. Reesink, S. Murphy, 1992, Vox sanguinis.

Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide.

C. Schiffer, S. Srinivasan, 2009, Leukemia research.

What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?

R. Larson, M. Baccarani, G. Martinelli, 2014 .

Functional evaluation of circulating leukemic cells in acute non-lymphocytic leukemia

C. Schiffer, P. Wiernik, 1977 .

C. Schiffer, A. Munkarah, Sanjeev Kumar, 2011, Gynecologic oncology.

Platelet transfusion therapy for patients with leukemia.

C. Schiffer, J. Aisner, P. Wiernik, 1978, Progress in clinical and biological research.

Platelet transfusion therapy for the cancer patient.

C. Schiffer, M. Heyman, 1990, Seminars in oncology.

Seminars in oncology

C. Schiffer, 2001 .

Pentostatin treatment for hairy cell leukemia patients who failed initial therapy with recombinant alpha-interferon: a report of CALGB study 8515.

S. Horning, R. Mick, D. Budman, 1994, Leukemia.

Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: long-term follow-up results of study by Cancer and Leukemia Group B.

C. Bloomfield, K. Rai, R. Silver, 1995, Leukemia.

Change in Liver Iron Concentration (LIC), Serum Ferritin (SF) and Labile Plasma Iron (LPI) Over 1 Year of Deferasirox (DFX/Exjade®) Therapy in a Cohort of Myelodysplastic Patients

P. Greenberg, C. Schiffer, C. Koller, 2008 .

P104 Change in liver iron concentration (LIC), serum ferritin (SF) and labile plasma iron (LPI) over 1 year of deferasirox (Exjade®) therapy in a cohort of patients with MDS

P. Greenberg, C. Schiffer, C. Koller, 2009 .

Patient-Reported Functional Outcomes in Patients with Chronic Myeloid Leukemia after Stopping Tyrosine Kinase Inhibitors.

K. Weinfurt, J. Radich, R. Larson, 2021, Journal of the National Cancer Institute.

study : Presented in part at the 43rd Annual Meeting of The American chronic myelogenous leukemia in myeloid blast crisis: results of a phase II Imatinib induces hematologic and cytogenetic responses in patients with

R. Larson, F. Mandelli, N. Russell, 2013 .

Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.

C. Schiffer, K. Bohlke, K. Anderson, 2017, Journal of Oncology Practice.

Cancer and Leukemia Group B Studies in Relapsed AML

P. Amrein, C. Schiffer, E. Lee, 1992 .

patients with de novo acute myeloid leukemia : results from Cancer and success , cumulative incidence of relapse , and overall survival in adult Pretreatment cytogenetic abnormalities are predictive of induction

C. Bloomfield, J. Byrd, R. Larson, 2002 .

Chemotherapy‐induced lactose intolerance in adults

H. Parnes, C. Schiffer, C. Schiffer, 1994, Cancer.

Long-term follow-up of advanced Hodgkin's disease patients treated with a combination of streptozotocin, lomustine (CCNU), doxorubicin and bleomycin (SCAB)

C. Schiffer, P. Wiernik, 2004, Journal of Cancer Research and Clinical Oncology.

Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both?

C. Schiffer, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B study.

C. Bloomfield, M. L. Le Beau, W. Stock, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States

Martin C. Müller, R. Larson, M. Baccarani, 2016, Journal of the National Cancer Institute.

Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia

K. Weinfurt, J. Radich, R. Larson, 2018, BMC Cancer.

Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML

G. Rosti, J. Cortes, M. Deininger, 2020 .

Lymphocytosis Following First-Line Treatment for CML In Chronic Phase with Dasatinib Is Associated with Improved Responses: A Comparison with Imatinib

J. Cortes, G. Saglio, C. Schiffer, 2010 .

Association of lymphocytosis following treatment with dasatinib with response and outcome.

J. Cortes, G. Saglio, C. Schiffer, 2010 .

OPTIC primary analysis: A dose-optimization study of 3 starting doses of ponatinib (PON).

G. Rosti, M. Deininger, C. Chuah, 2021 .

Combination chemotherapy with diaziquone and amsacrine in relapsed and refractory acute nonlymphocytic leukemia: a Cancer and Leukemia Group B Study.

R. Mayer, C. Schiffer, B. Peterson, 1987, Cancer treatment reports.

A phase II trial of m‐AMSA in the treatment of advanced gynecologic malignancies

C. Schiffer, D. Brenner, J. Aisner, 1982, American journal of clinical oncology.

Clinical and cytogenetic correlations of abnormal megakaryocytopoiesis in patients with acute leukemia and chronic myelogenous leukemia in blast crisis.

J. Testa, C. Schiffer, E. Lee, 1990, Leukemia.

Platelet transfusion support for patients with cancer and hematologic malignancies

C. Schiffer, Clarence Sarkodee‐Adoo, 1996, Current opinion in hematology.

The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States

Aaron N. Winn, J. Ruterbusch, J. Beebe-Dimmer, 2020, Cancer.

Critical Shortage of African American Medical Oncologists in the United States.

A. Shields, T. Albrecht, L. Penner, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Philadelphia chromosome‐positive acute leukemia: Morphologic and clinical correlations

J. Testa, C. Schiffer, G. Helenglass, 1987, American journal of hematology.

Asciminib for CML: same target, new arrow.

C. Schiffer, 2021, Blood.

Very Poor Survival of Patients with AML Who Relapse after Achieving a First Complete Remission: The Eastern Cooperative Oncology Group Experience.

C. Bloomfield, Xiaochun Li, W. Woods, 2005 .

Intensive postremission therapy in adults with acute nonlymphocytic leukemia with ara-C by continuous infusion or bolus administration: preliminary results of a CALGB phase I study.

K. Rai, R. Mayer, R. Silver, 1985, Seminars in oncology.

Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal☆

G. Superti-Furga, T. Haferlach, A. Órfão, 2017, EBioMedicine.

Acute Lymphocytic Leukemia in Adults

R. Larson, C. Schiffer, 2000 .

Surgery in acute leukemia: A review of 167 operations in thrombocytopenic patients

J. Matthews, C. Schiffer, J. Aisner, 1987, American journal of hematology.

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.

M. Baccarani, C. Sawyers, B. Druker, 2002, Blood.

All-trans-Retinoic Acid in Acute Promyelocytic Leukemia

C. Bloomfield, F. Appelbaum, C. Willman, 2000 .

Fate in Humans of the Plasticizer, Di‐2‐Ethylhexyl Phthalate, Arising from Transfusion of Platelets Stored in Vinyl Plastic Bags

R. Rubin, C. Schiffer, C. Schiffer, 2003, Transfusion.

Morphologic characteristics of acute lymphoblastic leukemia (ALL) with abnormalities of chromosome 8, band q24

C. Bloomfield, C. Schiffer, M. L. Le Beau, 1992, American journal of hematology.

Trisomy 13: a new recurring chromosome abnormality in acute leukemia.

C. Bloomfield, H. Döhner, J. Testa, 1990, Blood.

Filtration leukapheresis (FL) and granulocytes.

C. Schiffer, J. Aisner, 1978, Blood.

Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762).

C. Bloomfield, C. Schiffer, R. Larson, 1992, Blood.

Histocompatible platelet transfusion for patients with leukemia

J. Dutcher, C. Schiffer, J. Aisner, 1982 .

Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach

M. Cazzola, H. Döhner, D. Arber, 2022, American journal of hematology.

Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia.

C. Bloomfield, C. Schiffer, J. Griffin, 1986, Blood.

Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364.

C. Bloomfield, M. Czuczman, C. Schiffer, 1999, Blood.

Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11.

M. Caligiuri, C. Bloomfield, C. Croce, 1996, Cancer research.

Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia

K. Weinfurt, J. Radich, Li Lin, 2018, BMC Cancer.

The spectrum of musculoskeletal symptoms in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors.

C. Schiffer, M. Diab, 2019, Leukemia research.

Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study

Jeffrey A Jones, M. Grever, G. Lozanski, 2016 .

High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361).

C. Bloomfield, C. Schiffer, R. Larson, 2001, Blood.

Hepatitis in patients with acute nonlymphocytic leukemia.

J. Hoofnagle, M. Gaffey, C. Schiffer, 1983, The American journal of medicine.

To what extent can mathematical modeling inform the design of clinical trials? The example of safe dose reduction of tyrosine kinase inhibitors in responding patients with chronic myeloid leukemia

J. Schiffer, C. Schiffer, 2018, Haematologica.

Donor selection for alloimmunized patients by platelet crossmatching of random‐donor platelet concentrates

C. Schiffer, B. O’Connell, 1990, Transfusion.

Sounding board: Platelet transfusions from single donors.

C. Schiffer, S. Slichter, 1982, The New England journal of medicine.

New patterns of genetic instability in chronic myeloid leukemia: interesting, but not ready for clinical use

C. Schiffer, 2023, Haematologica.

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia

C. Schiffer, R. Ramchandren, 2009 .

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia

C. Schiffer, R. Ramchandren, 2009 .

Acute myeloid leukaemia in adults

F. Ferrara, C. Schiffer, 2013, The Lancet.

Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.

Z. Cabantchik, P. Greenberg, G. Warsi, 2010, Leukemia research.

Molecular characterization of AML: a significant advance or just another prognostic factor?

C. Schiffer, 2008, Best practice & research. Clinical haematology.

Strategies for managing refractoriness to platelet transfusions.

C. Schiffer, M. E. Dan, 2003, Current hematology reports.

Intensified Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia: An Update of CALGB 8525

Roger B. Davis, R. Mayer, C. Schiffer, 1997 .